NCT03849469: A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

NCT03849469
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: MSI-H, DNA damage repair mutations
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: TNBC patients are not required to have MSI-H or DNA damage repair deficient tumore
Exclusions: 
https://ClinicalTrials.gov/show/NCT03849469

Comments are closed.

Up ↑